Shield Therapeutics (LON:STX) Stock Price Passes Below Fifty Day Moving Average – Should You Sell?

Shares of Shield Therapeutics plc (LON:STX) passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 3.06 ($0.04) and traded as low as GBX 3 ($0.04). Shield Therapeutics shares last traded at GBX 3.10 ($0.04), with a volume of 893,979 shares traded.

Shield Therapeutics Stock Performance

The firm’s 50 day moving average price is GBX 3.07 and its 200-day moving average price is GBX 3.39. The company has a debt-to-equity ratio of 3,691.50, a quick ratio of 2.16 and a current ratio of 1.05. The firm has a market capitalization of £29.61 million, a PE ratio of -0.77 and a beta of 1.42.

Insider Transactions at Shield Therapeutics

In related news, insider Anders Lundstrom purchased 575,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average cost of GBX 4 ($0.05) per share, with a total value of £23,000 ($29,750.36). Corporate insiders own 62.16% of the company’s stock.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.